Health utilities using the EQ-5D in studies of cancer

被引:224
作者
Pickard, A. Simon
Wilke, Caitlyn T.
Lin, Hsiang-Wen
Lloyd, Andrew
机构
[1] Univ Illinois, Coll Pharm, Ctr Pharmacoecon Res, Chicago, IL 60612 USA
[2] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60612 USA
[3] Univ Illinois, Coll Pharm, Dept Pharm Adm, Chicago, IL 60612 USA
[4] Hines VA Hosp, Midw Ctr Hlth Serv & Policy Res, Hines, IL USA
[5] United BioSource Corp, Hlth Care Analyt Grp, London, England
关键词
D O I
10.2165/00019053-200725050-00002
中图分类号
F [经济];
学科分类号
02 ;
摘要
Cancer is one of the most frequent disease- specific applications of the EQ-5D. The objective of this review was to summarise evidence to support the validity and reliability of the EQ-5D in cancer, and to provide a catalogue of utility scores based on the use of the EQ-5D in clinical trials and in studies of patients with cancer. A structured literature search was conducted in EMBASE and MEDLINE to identify papers using key words related to cancer and the EQ-5D. Original research studies of patients with cancer that reported EQ-5D psychometric properties, responses and/or summary scores were included. Of 57 identified articles, 34 were selected for inclusion, where 12 studies reported evidence of validity or reliability and 31 reported EQ-5D responses or summary scores. The majority of investigations using the EQ-5D concerned patients with prostate cancer (n = 4), breast cancer (n = 4), cancers of the digestive system (n = 7) and Hodgkin and/or non-Hodgkin lymphoma. (n = 3). Mean index- based scores ranged from 0.33 (SD 0.4) to 0.93 (SD 0.12) and visual analogue scale scores ranged from 43 (SD 13.3) to 84 (SD 12.0) across subtypes of cancer. A substantial and growing body of literature using the EQ-5D in cancer that supports the validity and reliability of EQ-5D in cancer has emerged. This review provides utility estimates for cancer patients across a wide range of cancer subtypes, treatment regimens and tumour stage(s) that may inform the modelling of outcomes in economic evaluations of cancer treatment.
引用
收藏
页码:365 / 384
页数:20
相关论文
共 54 条
[21]   Comparison of the EQ-5D and SF-12 in an adult US sample [J].
Johnson, JA ;
Coons, SJ .
QUALITY OF LIFE RESEARCH, 1998, 7 (02) :155-166
[22]   A role for P-glycoprotein in regulating cell death [J].
Johnstone, RW ;
Ruefli, AA ;
Tainton, KM ;
Smyth, MJ .
LEUKEMIA & LYMPHOMA, 2000, 38 (1-2) :1-+
[23]   Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer [J].
Korfage, IJ ;
Essink-Bot, ML ;
Borsboom, GJJM ;
Madalinska, JB ;
Kirkels, WJ ;
Habbema, JDF ;
Schröder, FH ;
de Koning, HJ .
INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (02) :291-296
[24]   Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30 [J].
Krabbe, PFM ;
Peerenboom, L ;
Langenhoff, BS ;
Ruers, TJM .
QUALITY OF LIFE RESEARCH, 2004, 13 (07) :1247-1253
[25]   Validation of a functional evaluation system in patients with musculoskeletal tumors [J].
Lee, SH ;
Kim, DJ ;
Oh, JH ;
Han, HS ;
Yoo, KH ;
Kim, HS .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2003, (411) :217-226
[26]   Self-reported health status of the general adult US population as assessed by the EQ-5D and Health Utilities Index [J].
Luo, N ;
Johnson, JA ;
Shaw, JW ;
Feeny, D ;
Coons, SJ .
MEDICAL CARE, 2005, 43 (11) :1078-1086
[27]  
Mantovani G, 2004, CANCER EPIDEM BIOMAR, V13, P1651
[28]   A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss [J].
McMillan, DC ;
Wigmore, SJ ;
Fearon, KCH ;
O'Gorman, P ;
Wright, CE ;
McArdle, CS .
BRITISH JOURNAL OF CANCER, 1999, 79 (3-4) :495-500
[29]   Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement [J].
Moher, D ;
Cook, DJ ;
Eastwood, S ;
Olkin, I ;
Rennie, D ;
Stroup, DF .
LANCET, 1999, 354 (9193) :1896-1900
[30]   Treatment costs in Hodgkin's disease: A cost-utility analysis [J].
Norum, J ;
Angelsen, V ;
Wist, E ;
Olsen, JA .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (09) :1510-1517